(Circulation. 2000;101:1586.)
© 2000 American Heart Association, Inc.
Basic Science Reports |
Inhibition of Early Atherogenesis by Losartan in Monkeys With Diet-Induced Hypercholesterolemia
From Wake Forest University School of Medicine, Winston-Salem, NC (W.B.S., M.C.C., R.H.D., C.M.F.), and Merck & Co, West Point, Pa (S.K.).
Correspondence to William B. Strawn, DVM, PhD, Hypertension and Vascular Disease Center, Wake Forest University School of Medicine, Medical Center Blvd, Winston-Salem, NC 27157. E-mail bstrawn{at}wfubmc.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background—Angiotensin II may contribute to atherogenesis by facilitating the proliferative and inflammatory response to hypercholesterolemia. This study determined, in a primate model of diet-induced atherosclerosis, the effect of AT1 blockade on fatty-streak formation, plasma lipids, and surrogate markers of vascular injury.
Methods and Results—Male cynomolgus monkeys fed a diet containing
0.067 mg cholesterol/kJ for 20 weeks were given
losartan (180 mg/d, n=6) or vehicle (n=8) for 6 weeks starting
at week 12 of the dietary regimen. Arterial pressure, heart
rate, plasma total and lipoprotein cholesterol
concentrations, and lipoprotein particle sizes and subclass
distributions were unaffected by treatment. Losartan caused
significant (P<0.05) increases in plasma
angiotensin II and angiotensin-(1–7). Compared
with vehicle-treated controls, losartan reduced the extent of
fatty streak in the aorta, the coronary arteries, and the
carotid arteries by 
50% (P<0.05). A significant
(P<0.05) reduction in the susceptibility of LDL to in
vitro oxidation, serum levels of monocyte chemoattractant protein-1,
and circulating monocyte CD11b expression were also associated with
losartan treatment. In addition, serum levels of vascular cell
adhesion molecule-1 and E-selectin did not change during treatment but
increased after discontinuation of losartan. Serum C-reactive
protein, platelet aggregability, and white cell counts were not
modified by losartan.
Conclusions—This study demonstrates for the first time an antiatherogenic effect of AT1 receptor blockade in nonhuman primates. Losartan inhibited fatty-streak formation through mechanisms that may include protection of LDL from oxidation and suppression of vascular monocyte activation and recruitment factors.
Key Words: atherosclerosis • angiotensin • cell adhesion molecules • hypercholesterolemia • lipoproteins
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The evolution of atherosclerosis may be influenced by actions of angiotensin II (Ang II) on endothelial function,1 2 monocyte activation and binding,3 vascular smooth muscle cell proliferation and migration,4 and oxidation of LDL.5 Detection of ACE and Ang II in human atheroma suggests a role for angiotensin peptides in atherogenesis.6 Arterial deposition of oxidized LDL is stimulated by Ang II, and compared with native LDL, Ang II–modified LDL interacts with macrophage scavenger receptors at an enhanced rate.7 Furthermore, Ang II activates circulating monocytes, adhesion molecules, and cytokines.3 These findings suggest that Ang II may contribute to the vascular inflammatory response observed in early diet-induced atherosclerosis.
Hypercholesterolemia-induced atherosclerosis in cynomolgus monkeys, which bears marked similarities to the disease in humans,8 is inhibited by the administration of ACE inhibitors.9 To more directly evaluate the role of Ang II in atherogenesis, we investigated whether AT1 receptor blockade retards atherogenesis in this species by measuring the extent of fatty-streak formation, lipoprotein atherogenicity, the activation status of circulating monocytes and platelets, and levels of circulating adhesion molecules.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animals and Experimental Protocol
Twenty adult male cynomolgus (Macaca fascicularis) monkeys (weight, 4 to 7 kg) were fed an atherogenic diet containing 0.067 mg cholesterol/kJ for 20 weeks. The diet was prepared on site and given to the animals once daily at the same time each day. Water was available ad libitum. Surgical procedures were done under sterile conditions after induction of anesthesia with ketamine hydrochloride (40 mg/kg IM, Fort Dodge Laboratories). All procedures were performed in accordance with the standards of the Department of Health and Human Resources and were approved by the Institutional Animal Care and Use Committee.
Monkeys were randomized by plasma total cholesterol (TC) concentrations at week 12 of the dietary regimen to receive a 6-week infusion of either losartan or vehicle (50% dimethylsulfoxide/50% distilled H2O, vol/vol) via osmotic minipumps (model 2 ML4, Alza Corp) inserted into the interscapular tissue. Losartan, dissolved in vehicle to a final concentration rate of 1.0 mg/µL, was administered at a rate of 2.5 mg/h. Two weeks after cessation of treatment, monkeys were deeply anesthetized with a mixture of ketamine hydrochloride (40 mg/kg IM) and pentobarbital sodium (50 mg/kg IV). Whole-body perfusion with lactated Ringer’s solution was initiated via a left ventricular cannula at a pressure of 100 mm Hg. The heart was isolated, and coronary arteries were perfused in situ with 10% phosphate-buffered formalin (pH 7.4) for 1 hour. The epicardial segments of the left anterior descending (LAD), circumflex (LCx), and right (RCA) coronary arteries were removed and immersed in 10% phosphate-buffered formalin. Iliac and carotid arteries were placed in the same fixative for determination of TC concentrations. The aorta (from the aortic arch to the iliac bifurcation) was removed, cut open along the longitudinal axis, pinned flat, and immersed in fixative.
Physiological Studies
Variables were determined at week 12 of the dietary regimen
(baseline), again at weeks 3 and 6 of treatment, and at the end of the
recovery period. Triplicate measurements of arterial
pressure were obtained with an automatic sphygmomanometer in animals
lightly anesthetized with ketamine (10 mg/kg IM). Heart
rates were calculated from the average number of pulse waves per
time.
Laboratory Procedures
Samples of venous blood were drawn and, unless noted below,
collected into tubes with or without EDTA (Vacutainer, Becton
Dickinson) before the regular morning feeding for measurements of
plasma lipids, angiotensin peptides, hematological
variables, and serum markers.
Blood Cell Counts
Automated cell counts were determined in a cell counter (series
9000, Serono Baker Diagnostics) with the cell-size
discriminator optimized for this species. Leukocyte differential counts
were performed by counting 100 white blood cells on a Wright’s-stained
blood smear.
Monocyte CD11b Assays
Whole-blood immunophenotyping was performed in 50-µL samples
of venous blood diluted in 100 µL of PBS/0.1% BSA by
fluorescence-activated cell sorting analysis
using mouse-derived monoclonal antibodies to human CD14 (PE-conjugated,
clone My4, Beckman Coulter), CD45 (FITC-conjugated, clone 2B11, Dako),
and CD11b (FITC-conjugated, clone ICRF44, Pharmingen) receptors. The
monocyte acquisition gate was determined by 2-color analysis of
cells expressing high levels of
CD14+/CD45+ and by forward-
and side-scatter properties previously determined to discriminate
monocytes from granulocytes and lymphocytes in this
species.10 Expression of CD11b was assessed by
single-color analysis of fluorescence intensity of
cells within the gate established for monocyte acquisition. Monoclonal
antibodies were added at room temperature for 20 minutes. Cells were
washed once with 1 mL of PBS. Red blood cells were lysed (Whole Blood
Lysing Kit, Beckman Coulter), and after 2 additional washings, they
were resuspended in 500 µL of PBS/2%
paraformaldehyde and refrigerated until
analysis. Cell suspensions were analyzed within 24
hours of labeling on an EPICS (Beckman Coulter) flow cytometer using
EXPO cytometer software (Beckman Coulter). For each sample, a minimum
of 5000 cells were analyzed within the monocyte acquisition
gate. Results are reported as the mean fluorescence intensity
of cells expressing CD11b.
Platelet Thrombin Receptor Activation
Platelet-rich plasma prepared as previously
described11 was incubated at 37°C for 2 minutes and
stirred for 1 minute at 1100 rpm in an aggregometer (PAP 4-C, Biodata).
The thrombin receptor agonist SFLRRN-NH2 (5 to
1000 µmol/L) was added at various doses to stimulate
platelet aggregation. Results are reported as the concentration of
agonist that produced a half-maximal response
(C50).
Circulating Markers
ELISA kits were used to determine serum concentrations of
soluble monocyte chemoattractant protein (MCP)-1 (Cytoscreen
Immunoassay Kit, Biosource International), vascular cell adhesion
molecule (VCAM)-1, and E-selectin (R&D Systems, Inc). Serum C-reactive
protein (CRP) concentrations were determined by turbidimetric
immunoassay (ALPCO).
Biochemical Procedures
Plasma Cholesterol and Lipoprotein Profiles
Plasma TC was determined by enzymatic procedures, whereas HDL
cholesterol, LDL, VLDL, lipoprotein subclass distributions,
and particle sizes were determined by proton NMR
spectroscopy.12 A 360-MHz proton NMR spectrum (Siemens
Medical Systems; reconfigured by Analogic) of plasma specimens was
obtained at 45°C. Deconvolution of the lipid methyl group signal
envelope yielded the derived signal amplitudes broadcast for 14 modeled
lipoprotein subclasses. Particle size index (mass-weighted-average size
of particles within each lipoprotein class) was calculated by weighting
each subclass concentration by a numerical size designation, with large
values representing larger particle subclasses.
The susceptibility of LDL to in vitro oxidation was assessed by modification of the technique described by Esterbauer et al.13 Auto-oxidation was studied at 37°C in quartz cuvettes containing 3 mL of air-saturated 25 mmol/L phosphate buffer, pH 7.2, and 0.1 mol/L NaCl. The solution was mixed with 10 µg/mL LDL protein containing 3.6 µmol/L Cu+2 (PolyScience). EDTA and salts were removed by 48 hours of dialysis at 4°C against 25 mmol/L PBS containing 10 µmol/L DTPA with continuous nitrogen sparging. Conjugated diene formation was measured at 236 nm with a diode array spectrometer (model 8452, Hewlett Packard). Concentrations were calculated assuming e236 nm=26 000 mol/L per cm. The rates of oxidation and lag times were determined as previously described for LDL.14 Protein was measured with BSA (No. 4503, Sigma-Aldrich) as the standard.15 The lag phase is the interval between the intercept of the tangent of the slope of the absorbance curve during the diene conjugation phase with the time-scale axis, expressed in minutes. The oxidation rate was calculated from the slope of the absorbance curve during the propagation phase, expressed as pmol diene · min-1 · mg LDL protein-1.
Plasma Angiotensin Peptides
Plasma concentrations of Ang II and Ang-(1–7) were determined
as described previously.16 Samples of blood were placed in
tubes containing EDTA (25 mmol/L final concentration) and a
mixture of protease inhibitors (0.44 mmol/L
o-phenanthroline, 0.12 mmol/L pepstatin A, 1
mmol/L 4-chloromercuribenzoic acid) to prevent peptide degradation.
After centrifugation at 4°C, the plasma was frozen on
dry ice and stored at -20°C until analysis.
Plasma Losartan and EXP 3174
Plasma concentrations of losartan and the metabolite EXP
3174 were determined by high-performance liquid
chromatography (HPLC) separation/UV detection. The
solvent system consisted of 0.1% phosphoric acid (Phos, mobile phase
A) and 80% acetonitrile (ACN)/0.1% Phos (mobile phase B). The
gradient was 25% B isocratic for 5 minutes, 25% to 50% B linear for
30 minutes, and 50% B isocratic for 10 minutes at a flow rate of 0.35
mL/min at ambient temperature. Analysis was performed on an
HPLC (ABI) equipped with a narrow-bore Nova-Pak
C18 column (Waters 2.1x150 mm) and an
Aquapore C8 guard column (ABI, 3.2x15 mm).
Compounds were monitored at a wavelength of 254 nm (ABI 783 Spectroflow
detector), identified by comparison of their retention times with those
of standards. Peak areas were determined with a PC Chrom 24-bit data
acquisition system (H&S Scientific). The sensitivity of the HPLC
analysis was 10 pmol of losartan. Losartan
eluted at 19.9 minutes and EXP 3174 at 29.8 minutes. Before HPLC
analysis, plasma samples were extracted and concentrated on
Sep-Pak C18 columns (200 mg, Waters). Plasma (2
mL) was acidified with 0.1 Phos, applied to an activated column
(5 mL 80% ACN/0.1% Phos, 5 mL 0.1 Phos), and washed with 0.1% Phos
and 20% ACN/0.1% Phos. The compounds were eluted in 5 mL 80%
ACN/0.1% Phos, and the eluate was completely evaporated in a Savant
vacuum centrifuge.
Fatty-Streak Measurements
Aortas were stained by immersion for 24 hours in Sudan IV (in
38% isopropanol, optical density 0.220). Luminal surfaces were
digitally imaged by scanning (ScanJet 6200C, Hewlett Packard), and the
percentage of fatty-streak surface area was determined by digitizing
color images. The histological characteristics of fatty
streaks were confirmed by immunological detection.
Fifteen consecutive segments of the LAD, LCx, and RCA (5 mm in
length) were embedded in paraffin, cut, mounted on glass slides, and
stained with Verhoeff–van Gieson stain. Measurements of the intima
thickness and media cross-sectional areas were determined with an
imaging system (MCID, Imaging Research, Inc). The intima area was
determined by digitizing the area between the internal elastic lamina
(IEL) and the luminal surface of each coronary artery. Media
area size was calculated by use of the area within the external elastic
lamina and IEL.
Monoclonal antibodies to monocyte-macrophages (HAM-56,
Boehringer Mannheim) and smooth muscle cells (
-actin, Dako)
delineated cell types within vascular cross sections. The
immunoperoxidase-avidin-biotin complex system with nickel chloride
(NiCl) color modification was used on formalin-fixed paraffin-embedded
sections. Five-micrometer sections were deparaffinized and
rehydrated with PBS. Sections were preincubated with 3% normal horse
serum for 10 minutes. Diluted primary antibodies (HAM56, 1:6000;
-actin, 1:8000) were applied to the sections and incubated for 30
minutes. Sections were serially incubated with 1:200 dilutions in PBS
of biotinylated horse antimouse IgG (Vector Laboratories) for 30
minutes; avidin–biotinylated horseradish peroxidase complex (Vector
Laboratories) at 1:1 ratio, diluted 1:100 each in PBS for 30 minutes;
0.05% 3,3'-diaminobenzidine (Sigma-Aldrich) in 200 mL 0.05 mol/L
Tris buffer (pH 7.6) to which 2 mL of 3% hydrogen peroxide and 1.0 mL
of 8% NiCl solution were added for 10 minutes. Sections were
counterstained with hematoxylin, dehydrated in graded series of alcohol
concentrations, and covered with coverslips.
The carotid arteries were subjected to Folch extraction and detergent enzymatic digestion for determination of TC (Cholesterol/HP Kit, Boehringer-Mannheim) and free cholesterol (Free Cholesterol C Kit, Wako). Protein was determined as described.15
Statistics
ANOVA was used to determine within-group and between-group
differences at baseline, treatment, and recovery. The paired Student’s
t test was used where only baseline and treatment values are
reported. Square-root transformation of the intimal area in
coronary arteries was used to normalize the data before
analysis. All tests were 2-tailed, and probability values of
<0.05 were considered significant.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Studies were completed in 14 of 20 animals; 8 were randomized to vehicle treatment and 6 to losartan treatment. Experiments were interrupted in 4 animals because of aversion to the diet. Two additional animals were excluded from study because their plasma TC concentrations fell outside the 95% CI at week 12 of the dietary regimen.
Body weights in the vehicle (5.03±0.10 kg) and losartan
(5.10±0.15 kg) groups were not different (P>0.05) at
baseline and during the treatment and recovery periods (Figure 1
). Plasma TC concentrations at week 12
of the dietary regimen averaged 8.12±1.03 and 8.04±0.78 mmol/L
in animals randomized to vehicle or losartan treatment,
respectively (P>0.05).
|
) or vehicle (
)
before treatment (0 to 12 weeks), during treatment (weeks 13 to 19),
and after interruption of treatment (week 20). Results are mean±SEM.
*P<0.05, statistical difference in plasma
cholesterol levels between monkeys randomized to either
losartan or vehicle at week 12 of dietary regimen.
Hemodynamic and angiotensin peptide data
are presented in Figure 2. Mean
arterial pressures at week 12 of the diet and before
randomization to vehicle or losartan treatments were 48±5 and
56±5 mm Hg, respectively (P>0.05). After 6 weeks of
treatment, mean arterial pressures were 58±3 and
58±4 mm Hg (P>0.05) in losartan- and
vehicle-treated animals, respectively. Although systolic and
diastolic pressures were never different between treatment
groups, systolic pressure in the losartan group was
lower (P<0.05) than baseline values at week 4 of treatment.
Cardiac rates were not different between vehicle- and
losartan-treated animals throughout the study. Vehicle-treated
monkeys had lower heart rates than at baseline at the completion of the
treatment period and at week 2 of the recovery period. Plasma Ang II
and Ang-(1–7) concentrations were significantly increased in animals
given losartan. At weeks 3 and 6 of treatment, plasma levels of
losartan averaged 377±67 and 464±82 ng/mL, respectively. EXP
3174, the active metabolite of losartan, was detected in the
plasma at week 2 (24±6 ng/mL) but not at week 6 of treatment.
|
Losartan had no effect on plasma cholesterol
concentrations, the size of lipoprotein particles, or their
distribution within subclasses (Table).
Figure 3 illustrates that the
susceptibility of LDL to lipid peroxidation (lag time to diene
formation and rate of oxidation) in the presence of
CuSO4 was not different at baseline between
vehicle- and losartan-treated animals. In contrast, the lag
time of the CuSO4-induced LDL oxidation was
significantly increased (P<0.05) compared with
vehicle-treated monkeys at week 6 of losartan treatment. The
rate of oxidation was unaffected by treatment.
|
|
Effect of Losartan on Atherosclerosis
Figure 4 shows
representative examples of fatty-streak distribution in
the aorta of vehicle- and losartan-treated monkeys. In
vehicle-treated monkeys (Figure 4, a and b), sudanophilic areas
encompassed both branching and nonbranching areas of the thoracic
aorta, whereas fatty streaks were sparse and more prevalent in
branching areas of the abdominal aorta. The extent of sudanophilic
areas was markedly less in losartan-treated animals (Figure 4, c and d). Figure 5a shows that
the layer of foam cells in aortic lesions consistently stopped
at the internal elastic lamina (IEL) and that fatty streaks were
composed primarily of lipid-loaded HAM-56–positive macrophages
(Figure 5b). The histological features of aortic
lesions were comparable between vehicle- and losartan-treated
monkeys. In contrast, Figure 6
illustrates the differential effect of losartan treatment on
the histological characteristics of fatty streaks in
the left anterior descending coronary artery (LAD). Whereas in
vehicle-treated animals, intimal foam cell accumulation was associated
with IEL disruption (Figure 6a) and a predominance of cells
immunopositive for -actin (Figure 6c), a comparable section
from a losartan-treated monkey showed a reduction of fatty
streak composed of macrophage-derived foam cells and no
disruption of the IEL (Figure 6, b and d).
|
|
|
Losartan had a pronounced effect on the extent of fatty streak
(Figure 7). Administration of
losartan was associated with significantly (P<0.05)
less fatty streak in the arch (48%), thoracic (52%), and abdominal
(54%) aorta than in vehicle-treated monkeys. The intimal area was less
(P<0.05) in the LAD and left circumflex coronary
artery (LCx), whereas media area was smaller (P<0.05) only
in the LAD (vehicle, 0.220±0.020 mm2;
losartan, 0.170±0.020 mm2).
Furthermore, the inhibition of fatty-streak formation by
losartan was associated with a comparatively lower
(P<0.05) carotid artery content of TC and esterified
cholesterol.
|
Effect of Losartan on Immune Status and Circulating
Markers
Monocyte cell count was not different between vehicle
(2.32±0.57x106/mL) and losartan
(3.1±0.43x106/mL) groups at baseline and
remained unaltered during treatment and recovery periods. Baseline,
treatment, and recovery values for monocyte and platelet activation
along with levels of soluble monocyte chemoattractant protein (MCP)-1,
vascular cell adhesion molecule (VCAM)-1, E-selectin, and C-reactive
protein (CRP) are shown in Figure 8.
Surface expression of CD11b by circulating monocytes was unaffected by
vehicle but was significantly (P<0.05) reduced in
losartan-treated monkeys both at week 6 of treatment and at the
end of the recovery period. Platelet aggregability did not differ
between vehicle- and losartan-treated animals. Serum MCP-1 was
significantly (P<0.05) reduced at week 6 of
losartan treatment, with values returning to pretreatment
levels during the recovery period. Baseline concentrations of VCAM-1
and E-selectin were higher in the group randomized to losartan
than in vehicle-treated monkeys (P<0.05). The difference
persisted during the period of infusion. Within each treatment group,
however, VCAM-1 and E-selectin concentrations were not different at
baseline and week 6 of the infusion period. Conversely, VCAM-1 and
E-selectin concentrations showed a significant increase 2 weeks after
discontinuation of the infusion in the group of monkeys given
losartan. CRP concentrations were not different in vehicle- and
losartan-treated animals throughout the study.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
The data presented here represent the first demonstration of Ang II AT1 receptor–mediated fatty-streak formation in a primate model of human atherosclerosis. Plasma concentrations of losartan achieved by the method of continuous subcutaneous infusion used in this study were within the range reported in human subjects given the standard dose of 50 to 100 mg once daily.17 The extent of hypercholesterolemia-induced fatty streak in aorta and coronary arteries of losartan-treated monkeys was significantly less than in vehicle-treated monkeys and was associated with comparatively lower carotid artery content of TC and esterified cholesterol. These findings agree with results in rabbits18 19 and monkeys9 chronically treated with ACE inhibitors. In these studies, however, blood pressure and plasma lipid concentrations were reduced by the treatments. The inverse relationship between losartan and atherogenesis found in the present study suggests that AT1 receptor–mediated fatty-streak formation is unrelated to changes in blood pressure or lipid subclass concentrations and distributions, because these variables were unaffected by the treatment. These findings differ from observations in rabbits, in which only the dose of irbesartan that lowered blood pressure inhibited atherosclerosis.20
Evidence for antiatherogenic mechanisms related to the pronounced fatty-streak inhibition by losartan include a reduced susceptibility of LDL to in vitro CuSO4-induced oxidation, deactivation of circulating monocytes, and suppression of serum soluble MCP-1 levels. Keidar et al21 showed that losartan reduced LDL peroxidation and atherosclerosis in apolipoprotein E–deficient mice. Although there is no definitive proof that the resistance of LDL to in vitro oxidation reflects the peroxidation potential in vivo, our findings concur with other studies showing that the susceptibility of LDL for oxidation is related to the severity of atherosclerosis.21 Because CD11b expression is elevated by hypercholesterolemia,22 it reflects not only monocyte activation but also the propensity for adhesion to endothelium. The deactivation of monocytes by losartan may thus inhibit one of the cardinal events in atherogenesis. We showed previously that losartan inhibited the activation and adhesion of monocytes to the vascular endothelium of [mRen-2]27 transgenic hypertensive rats by a mechanism that is independent of blood pressure.23 Although the soluble adhesion molecules measured in this study are not yet completely defined as surrogate markers of atherogenesis, the significant reduction in MCP-1 levels and its rebound along with VCAM-1 and E-selectin after discontinuation of treatment in losartan-treated monkeys suggests that the antagonist had an inhibitory effect on monocyte recruitment factors. The antiatherogenic effect of losartan was not due to blockade of an acute inflammatory response. Our studies showed that losartan had no effect on serum CRP, platelet aggregability, and white cell counts. These findings suggest that losartan selectively inhibited atherogenesis, in part through protection of LDL from oxidation and suppression of AT1-mediated monocyte activation and recruitment. The increase in plasma Ang II and Ang-(1–7) may also contribute to the antiatherogenic actions of losartan, especially when injury-induced vascular smooth muscle cell proliferation is involved, because AT2 receptor stimulation and Ang-(1–7) administration mediate antiproliferative responses.24
In summary, losartan inhibited the development of fatty streak and reduced media area of coronary arteries by a mechanism that was independent of arterial pressure and plasma lipids. The reduction in the extent of fatty streak was accompanied by decreases in the carotid artery content of TC and esterified cholesterol, measures of LDL peroxidation, and monocyte activation. We conclude that the novel effects of losartan on early atherogenesis may extend the therapeutic profile of Ang II antagonists in the prevention of human vascular disease, an interpretation that agrees with the observation that atherogenesis is associated with upregulation of AT1 receptors.25
|
Acknowledgments |
|---|
This study was supported by grants PO1-HL-51952 and HL-56973 from the NHLBI and a Medical School Grant from Merck & Co. We thank Dr Ron Smith of Merck Inc for his efforts in procuring losartan potassium and Sam Rankin of the Section of Comparative Medicine for technical assistance.
Received July 19, 1999; revision received October 12, 1999; accepted October 21, 1999.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Ferrario CM, Deitch JS, Dean RH, Strawn WB. Hypertension and atherosclerosis: a mechanistic understanding of disease progression. Cardiovasc Risk Factors. 1996;6:299–310.
2. Clozel M, Kuhn H, Hefti F, Baumgartner HR.
Endothelial dysfunction and
subendothelial monocyte macrophages in
hypertension. Hypertension. 1991;18:132–141.
3. Kim JA, Berliner JA, Nadler JL. Angiotensin II increases monocyte binding to endothelial cells. Biochem Biophys Res Commun. 1996;226:862–868.[Medline] [Order article via Infotrieve]
4. Kubo A, Fukuda N, Soma M, Izumi Y, Kanmatsuse K. Inhibitory effect of an angiotensin II type 1 receptor antagonist on growth of vascular smooth muscle cells from spontaneously hypertensive rats. J Cardiovasc Pharmacol. 1996;27:58–63.[Medline] [Order article via Infotrieve]
5. Yanagitani Y, Rakugi A, Okamura A, Moriguchi K, Takiuchi S, Ohishi M, Suzuki M, Suzuki K, Higaki J, Ogihara T. Angiotensin II type 1 receptor–mediated peroxide production in human macrophages. Hypertension. 1999;33(pt II):II-335–II-339.
6. Potter DD, Sobey CG, Thompkins PK, Rossen JD, Heistad
DD. Evidence that macrophages in atherosclerotic lesions
contain angiotensin II. Circulation. 1998;98:800–807.
7. Keidar S, Kaplan M, Aviram M. Angiotensin
II–modified LDL is taken up by macrophages via the scavenger
receptor, leading to cellular cholesterol accumulation.
Arterioscler Thromb Vasc Biol. 1996;16:97–105.
8. Masuda J, Ross R. Atherogenesis during low-level
hypercholesterolemia in the nonhuman primate,
I: fatty streak formation.
Arteriosclerosis. 1990;10:164–177.
9. Song K, Shiota N, Takai S, Takashima H, Iwasaki H, Kim S, Miyazaki M. Induction of angiotensin converting enzyme and angiotensin II receptors in the atherosclerotic aorta of high-cholesterol fed Cynomolgus monkeys. Atherosclerosis. 1998;138:171–182.[Medline] [Order article via Infotrieve]
10. Otani I, Akari H, Nam K-H, Mori K, Suzuki E, Shibata H, Doi K, Terao K, Yosikawa Y. Phenotypic changes in peripheral blood monocytes of cynomolgus monkeys acutely infected with simian immunodeficiency virus. AIDS Res Hum Retrovir. 1998;14:1181–1186.[Medline] [Order article via Infotrieve]
11. Hale LP, Craver KT, Berrier AM, Sheffield MV, Case LD,
Owen J. Combination of fosinopril and pravastatin
decreases platelet response to thrombin receptor agonist in
monkeys. Arterioscler Thromb Vasc Biol. 1998;18:1643–1646.
12. Freedman DS, Otvos JD, Jeyarajah EJ, Barboriak JJ,
Anderson AJ, Walker JA. Relation of lipoprotein subclasses as measured
by proton nuclear magnetic resonance spectroscopy to coronary
artery disease. Arterioscler Thromb Vasc Biol. 1998;18:1046–1053.
13. Esterbauer H, Striegl G, Puhl H, Rotheneder M. Continuous monitoring of in vitro oxidation of human low density lipoprotein. Free Radic Res Commun. 1989;6:67–75.[Medline] [Order article via Infotrieve]
14. Thomas MJ, Rudel LL. Dietary fatty acids, low
density lipoprotein composition and oxidation and primate
atherosclerosis. J Nutr. 1996;126:1058S–1062S.
15. Lowry OH, Rosenbrough MJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. J Biol Chem. 1999;259:4177–4182.
16. Kohara K, Brosnihan KB, Ferrario CM. Angiotensin-(1–7) in the spontaneously hypertensive rat. Peptides. 1993;14:883–891.[Medline] [Order article via Infotrieve]
17. Ohtawa M, Takayama F, Saitoh K, Yoshinaga T, Nakashima M. Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans. Br J Clin Pharmacol. 1993;35:290–297.[Medline] [Order article via Infotrieve]
18. Chobanian AV, Haudenschild CC, Nickerson C, Drago R.
Antiatherogenic effect of captopril in the Watanabe heritable
hyperlipidemic rabbit. Hypertension. 1990;15:327–331.
19. Hernandez A, Barberi L, Ballerio R, Testini A, Ferioli R, Bolla M, Natali M, Folco G, Catapano AL. Delapril slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits. Atherosclerosis. 1998;137:71–76.[Medline] [Order article via Infotrieve]
20. Hope S, Brecher P, Chobanian AV. Comparison of the effects of AT1 receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis. Am J Hypertens. 1999;12:28–34.[Medline] [Order article via Infotrieve]
21. Keidar S, Attias J, Smith J, Breslow J, Hayek T. The angiotensin-II receptor antagonist, losartan, inhibits LDL lipid peroxidation and atherosclerosis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 1997;236:622–625.[Medline] [Order article via Infotrieve]
22. Weber C, Erl W, Weber KSC, Weber PC. HMF-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997;30:1212–1217.[Abstract]
23. Strawn WB, Gallagher PE, Tallant EA, Ganten D, Ferrario CM. Angiotensin II AT1-receptor blockade inhibits monocyte activation and adherence in transgenic (mRen2)27 rats. J Cardiovasc Pharmacol. 1999;33:341–351.[Medline] [Order article via Infotrieve]
24. Strawn WB, Ferrario CM, Tallant EA.
Angiotensin-(1–7) reduces smooth muscle growth after
vascular injury. Hypertension. 1999;33:207–211.
25. Yang BC, Phillips MI, Mohuczy D, Meng H, Shen L, Mehta
P, Mehta JL. Increased angiotensin II type 1 receptor
expression in hypercholesterolemic
atherosclerosis in rabbits. Arterioscler Thromb
Vasc Biol. 1998;18:1433–1439.
This article has been cited by other articles:
 |
|
 |
|
  B. Ramkhelawon, J. Vilar, D. Rivas, B. Mees, R. de Crom, A. Tedgui, and S. Lehoux Shear Stress Regulates Angiotensin Type 1 Receptor Expression in Endothelial Cells Circ. Res., October 23, 2009; 105(9): 869 - 875. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Fortuno, J. Bidegain, P. A. Robador, J. Hermida, J. Lopez-Sagaseta, O. Beloqui, J. Diez, and G. Zalba Losartan Metabolite EXP3179 Blocks NADPH Oxidase-Mediated Superoxide Production by Inhibiting Protein Kinase C: Potential Clinical Implications in Hypertension Hypertension, October 1, 2009; 54(4): 744 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kappert, O. Tsuprykov, J. Kaufmann, J. Fritzsche, I. Ott, M. Goebel, I. N. Bahr, P.-L. Hassle, R. Gust, E. Fleck, et al. Chronic Treatment With Losartan Results in Sufficient Serum Levels of the Metabolite EXP3179 for PPAR{gamma} Activation Hypertension, October 1, 2009; 54(4): 738 - 743. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q. Tian, R. Miyazaki, T. Ichiki, I. Imayama, K. Inanaga, H. Ohtsubo, K. Yano, K. Takeda, and K. Sunagawa Inhibition of Tumor Necrosis Factor-{alpha}-Induced Interleukin-6 Expression by Telmisartan Through Cross-Talk of Peroxisome Proliferator-Activated Receptor-{gamma} With Nuclear Factor {kappa}B and CCAAT/Enhancer-Binding Protein-{beta} Hypertension, May 1, 2009; 53(5): 798 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Schindler ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist`s perspective after publication of the results of ONTARGET Therapeutic Advances in Cardiovascular Disease, August 1, 2008; 2(4): 233 - 248. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Sendra, V. Llorente-Cortes, P. Costales, C. Huesca-Gomez, and L. Badimon Angiotensin II upregulates LDL receptor-related protein (LRP1) expression in the vascular wall: a new pro-atherogenic mechanism of hypertension Cardiovasc Res, June 1, 2008; 78(3): 581 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Nussberger, J.-F. Aubert, K. Bouzourene, M. Pellegrin, D. Hayoz, and L. Mazzolai Renin Inhibition by Aliskiren Prevents Atherosclerosis Progression: Comparison With Irbesartan, Atenolol, and Amlodipine Hypertension, May 1, 2008; 51(5): 1306 - 1311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Vinh, R. E. Widdop, G. R. Drummond, and T. A. Gaspari Chronic angiotensin IV treatment reverses endothelial dysfunction in ApoE-deficient mice Cardiovasc Res, January 1, 2008; 77(1): 178 - 187. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. O. Stumpe, E. Agabiti-Rosei, T. Zielinski, D. Schremmer, J. Scholze, P. Laeis, P. Schwandt, and M. Ludwig Original Research: Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study Therapeutic Advances in Cardiovascular Disease, December 1, 2007; 1(2): 97 - 106. [Abstract] [PDF]
|
|
|
|
|
|
I. Hernandez Schulman, M.-S. Zhou, and L. Raij Cross-Talk Between Angiotensin II Receptor Types 1 and 2: Potential Role in Vascular Remodeling in Humans Hypertension, February 1, 2007; 49(2): 270 - 271. [Full Text] [PDF]
|
|
|
|
|
|
I. Imayama, T. Ichiki, K. Inanaga, H. Ohtsubo, K. Fukuyama, H. Ono, Y. Hashiguchi, and K. Sunagawa Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor {gamma} Cardiovasc Res, October 1, 2006; 72(1): 184 - 190. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. A.J. van der Linde, E. J.G. Sijbrands, F. Boomsma, and A. H. van den Meiracker Effect of Low-Density Lipoprotein Cholesterol on Angiotensin II Sensitivity: A Randomized Trial With Fluvastatin Hypertension, June 1, 2006; 47(6): 1125 - 1130. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-S. Zhou, I. H. Schulman, P. J. Pagano, E. A. Jaimes, and L. Raij Reduced NAD(P)H Oxidase in Low Renin Hypertension: Link Among Angiotensin II, Atherogenesis, and Blood Pressure Hypertension, January 1, 2006; 47(1): 81 - 86. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. C. Hall and N. Dalbeth Disease modification and cardiovascular risk reduction: two sides of the same coin? Rheumatology, December 1, 2005; 44(12): 1473 - 1482. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Sales, G. K. Sukhova, M. A. Lopez-Ilasaca, P. Libby, V. J. Dzau, and R. E. Pratt Angiotensin Type 2 Receptor Is Expressed in Murine Atherosclerotic Lesions and Modulates Lesion Evolution Circulation, November 22, 2005; 112(21): 3328 - 3336. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Takai, D. Jin, M. Muramatsu, K. Kirimura, H. Sakonjo, and M. Miyazaki Eplerenone Inhibits Atherosclerosis in Nonhuman Primates Hypertension, November 1, 2005; 46(5): 1135 - 1139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D M Shavelle Are angiotensin converting enzyme inhibitors beneficial in patients with aortic stenosis? Heart, October 1, 2005; 91(10): 1257 - 1259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Williams Recent hypertension trials: Implications and controversies J. Am. Coll. Cardiol., March 15, 2005; 45(6): 813 - 827. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Sola, M. Q.S. Mir, F. A. Cheema, N. Khan-Merchant, R. G. Menon, S. Parthasarathy, and B. V. Khan Irbesartan and Lipoic Acid Improve Endothelial Function and Reduce Markers of Inflammation in the Metabolic Syndrome: Results of the Irbesartan and Lipoic Acid in Endothelial Dysfunction (ISLAND) Study Circulation, January 25, 2005; 111(3): 343 - 348. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Daugherty, D. L. Rateri, H. Lu, T. Inagami, and L. A. Cassis Hypercholesterolemia Stimulates Angiotensin Peptide Synthesis and Contributes to Atherosclerosis Through the AT1A Receptor Circulation, December 21, 2004; 110(25): 3849 - 3857. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. S Richmond, E A. Tallant, P. E Gallagher, C. M Ferrario, and W. B Strawn Angiotensin II stimulates arachidonic acid release from bone marrow stromal cells Journal of Renin-Angiotensin-Aldosterone System, December 1, 2004; 5(4): 176 - 182. [Abstract] [PDF]
|
|
|
|
|
|
S. Wassmann, T. Czech, M. van Eickels, I. Fleming, M. Bohm, and G. Nickenig Inhibition of Diet-Induced Atherosclerosis and Endothelial Dysfunction in Apolipoprotein E/Angiotensin II Type 1A Receptor Double-Knockout Mice Circulation, November 9, 2004; 110(19): 3062 - 3067. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. T. Johnstone, A. S. Perez, I. Nasser, R. Stewart, A. Vaidya, F. Al Ammary, B. Schmidt, G. Horowitz, J. Dolgoff, J. Hamilton, et al. Angiotensin Receptor Blockade With Candesartan Attenuates Atherosclerosis, Plaque Disruption, and Macrophage Accumulation Within the Plaque in a Rabbit Model Circulation, October 5, 2004; 110(14): 2060 - 2065. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Mazzolai, M. A. Duchosal, M. Korber, K. Bouzourene, J. F. Aubert, H. Hao, V. Vallet, H. R. Brunner, J. Nussberger, G. Gabbiani, et al. Endogenous Angiotensin II Induces Atherosclerotic Plaque Vulnerability and Elicits a Th1 Response in ApoE-/- Mice Hypertension, September 1, 2004; 44(3): 277 - 282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Schieffer, C. Bunte, J. Witte, K. Hoeper, R. H. Boger, E. Schwedhelm, and H. Drexler Comparative effects of AT1-antagonism and angiotensin-converting enzyme inhibition on markers of inflammation and platelet aggregation in patients with coronary artery disease J. Am. Coll. Cardiol., July 21, 2004; 44(2): 362 - 368. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. V. Khan, S. Sola, W. B. Lauten, R. Natarajan, W. C. Hooper, R. G. Menon, S. Lerakis, and T. Helmy Quinapril, an ACE Inhibitor, Reduces Markers of Oxidative Stress in the Metabolic Syndrome Diabetes Care, July 1, 2004; 27(7): 1712 - 1715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Attia, O. Feron, R. Goldschmeding, L. H. Radermakers, N. D. Vaziri, P. Boer, J.-L. Balligand, H. A. Koomans, and J. A. Joles Hypercholesterolemia in Rats Induces Podocyte Stress and Decreases Renal Cortical Nitric Oxide Synthesis via an Angiotensin II Type 1 Receptor-Sensitive Mechanism J. Am. Soc. Nephrol., April 1, 2004; 15(4): 949 - 957. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Candido, T. J. Allen, M. Lassila, Z. Cao, V. Thallas, M. E. Cooper, and K. A. Jandeleit-Dahm Irbesartan but Not Amlodipine Suppresses Diabetes-Associated Atherosclerosis Circulation, March 30, 2004; 109(12): 1536 - 1542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Cipollone, M. Fazia, A. Iezzi, B. Pini, C. Cuccurullo, M. Zucchelli, D. de Cesare, S. Ucchino, F. Spigonardo, M. De Luca, et al. Blockade of the Angiotensin II Type 1 Receptor Stabilizes Atherosclerotic Plaques in Humans by Inhibiting Prostaglandin E2-Dependent Matrix Metalloproteinase Activity Circulation, March 30, 2004; 109(12): 1482 - 1488. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wassmann, M. Stumpf, K. Strehlow, A. Schmid, B. Schieffer, M. Bohm, and G. Nickenig Interleukin-6 Induces Oxidative Stress and Endothelial Dysfunction by Overexpression of the Angiotensin II Type 1 Receptor Circ. Res., March 5, 2004; 94(4): 534 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Cipollone, B. Rocca, and C. Patrono Cyclooxygenase-2 Expression and Inhibition in Atherothrombosis Arterioscler Thromb Vasc Biol, February 1, 2004; 24(2): 246 - 255. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. M. Singh and J. L. Mehta Interactions Between the Renin-Angiotensin System and Dyslipidemia: Relevance in the Therapy of Hypertension and Coronary Heart Disease Arch Intern Med, June 9, 2003; 163(11): 1296 - 1304. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. S. Jacoby and D. J. Rader Renin-Angiotensin System and Atherothrombotic Disease: From Genes to Treatment Arch Intern Med, May 26, 2003; 163(10): 1155 - 1164. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Ben-Yehuda Hypertension, angiotensin II, aldosterone, and race J. Am. Coll. Cardiol., April 2, 2003; 41(7): 1156 - 1158. [Full Text] [PDF]
|
|
|
|
|
|
K. Fukuyama, T. Ichiki, K. Takeda, T. Tokunou, N. Iino, S. Masuda, M. Ishibashi, K. Egashira, H. Shimokawa, K. Hirano, et al. Downregulation of Vascular Angiotensin II Type 1 Receptor by Thyroid Hormone Hypertension, March 1, 2003; 41(3): 598 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Schieffer Interaction of interleukin-6 and angiotensin II in atherosclerosis: culprit for inflammation? Eur. Heart J. Suppl., January 1, 2003; 5(suppl_A): A25 - A30. [Abstract] [PDF]
|
|
|
|
|
|
U. Rueckschloss, M. T. Quinn, J. Holtz, and H. Morawietz Dose-Dependent Regulation of NAD(P)H Oxidase Expression by Angiotensin II in Human Endothelial Cells: Protective Effect of Angiotensin II Type 1 Receptor Blockade in Patients With Coronary Artery Disease Arterioscler Thromb Vasc Biol, November 1, 2002; 22(11): 1845 - 1851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Uehara, H. Urata, M. Ideishi, K. Arakawa, and K. Saku Chymase inhibition suppresses high-cholesterol diet-induced lipid accumulation in the hamster aorta Cardiovasc Res, September 1, 2002; 55(4): 870 - 876. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Opie and H.-H. Parving Diabetic Nephropathy: Can Renoprotection Be Extrapolated to Cardiovascular Protection? Circulation, August 6, 2002; 106(6): 643 - 645. [Full Text] [PDF]
|
|
|
|
|
|
A. R. Brasier, A. Recinos III, and M. S. Eledrisi Vascular Inflammation and the Renin-Angiotensin System Arterioscler Thromb Vasc Biol, August 1, 2002; 22(8): 1257 - 1266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Kramer, J. Sunkomat, J. Witte, M. Luchtefeld, M. Walden, B. Schmidt, R. H. Boger, W.-G. Forssmann, H. Drexler, and B. Schieffer Angiotensin II Receptor-Independent Antiinflammatory and Antiaggregatory Properties of Losartan: Role of the Active Metabolite EXP3179 Circ. Res., April 19, 2002; 90(7): 770 - 776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Aizawa, N. Ishizaka, S.-I. Usui, N. Ohashi, M. Ohno, and R. Nagai Angiotensin II and Catecholamines Increase Plasma Levels of 8-Epi-Prostaglandin F2{alpha} With Different Pressor Dependencies in Rats Hypertension, January 1, 2002; 39(1): 149 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. V. Khan, S. Navalkar, Q. A. Khan, S. T. Rahman, and S. Parthasarathy Irbesartan, an angiotensin type 1 receptor inhibitor, regulates the vascular oxidative state in patients with coronary artery disease J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1662 - 1667. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Li, H. Chen, and J. L. Mehta Angiotensin II via Activation of Type 1 Receptor Upregulates Expression of Endoglin in Human Coronary Artery Endothelial Cells Hypertension, November 1, 2001; 38(5): 1062 - 1067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y.-p. Sun, B.-q. Zhu, A. E. M. Browne, S. Pulukurthy, T. M. Chou, K. Sudhir, S. A. Glantz, P. C. Deedwania, K. Chatterjee, and W. W. Parmley Comparative Effects of ACE Inhibitors and an Angiotensin Receptor Blocker on Atherosclerosis and Vascular Function Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2001; 6(2): 175 - 181. [Abstract] [PDF]
|
|
|
|
|
|
S. Wassmann, U. Laufs, A. T. Baumer, K. Muller, K. Ahlbory, W. Linz, G. Itter, R. Rosen, M. Bohm, and G. Nickenig HMG-CoA Reductase Inhibitors Improve Endothelial Dysfunction in Normocholesterolemic Hypertension via Reduced Production of Reactive Oxygen Species Hypertension, June 1, 2001; 37(6): 1450 - 1457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V. Papademetriou, P. Mammillot, R. Redman, A. Notargiacomo, P. Narayan, and R. Lakshman Prevention of atherosclerosis by specific AT1-receptor blockade with candesartan cilexetil Journal of Renin-Angiotensin-Aldosterone System, March 1, 2001; 2(1_suppl): S77 - S80. [Abstract] [PDF]
|
|
|
|
 |
|
 A. Fournier, H. Mazouz, and J. M. Achard STOPPING at the CAPPP of good HOPE Nephrol. Dial. Transplant., January 1, 2001; 16(1): 185 - 187. [Full Text]
|
|
|
|
 |
|
 J. A.A. Borland, A. H. Chester, S. J. Rooker, J. Wharton, N. Davie, M. Amrani, and M. H. Yacoub Expression and function of angiotensin converting enzyme, chymase, and angiotensin II in the human radial artery and internal thoracic artery Ann. Thorac. Surg., December 1, 2000; 70(6): 2054 - 2063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Batalla, R. Alvarez, J. R. Reguero, S. Hevia, G. Iglesias-Cubero, V. Alvarez, A. Cortina, P. Gonzalez, M. M. Celada, A. Medina, et al. Synergistic Effect between Apolipoprotein E and Angiotensinogen Gene Polymorphisms in the Risk for Early Myocardial Infarction Clin. Chem., December 1, 2000; 46(12): 1910 - 1915. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Oelze, H. Mollnau, N. Hoffmann, A. Warnholtz, M. Bodenschatz, A. Smolenski, U. Walter, M. Skatchkov, T. Meinertz, and T. Munzel Vasodilator-Stimulated Phosphoprotein Serine 239 Phosphorylation as a Sensitive Monitor of Defective Nitric Oxide/cGMP Signaling and Endothelial Dysfunction Circ. Res., November 24, 2000; 87(11): 999 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Williams The renin angiotensin system and cardiovascular disease: hope or hype? Journal of Renin-Angiotensin-Aldosterone System, June 1, 2000; 1(2): 142 - 146. [PDF]
|
|
|
|
|
|
D. E. Vaughan AT1 Receptor Blockade and Atherosclerosis : Hopeful Insights Into Vascular Protection Circulation, April 4, 2000; 101(13): 1496 - 1497. [Full Text] [PDF]
|
|
|
|
|
|
C. Kramer, J. Sunkomat, J. Witte, M. Luchtefeld, M. Walden, B. Schmidt, R. H. Boger, W.-G. Forssmann, H. Drexler, and B. Schieffer Angiotensin II Receptor-Independent Antiinflammatory and Antiaggregatory Properties of Losartan: Role of the Active Metabolite EXP3179 Circ. Res., April 19, 2002; 90(7): 770 - 776. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||